<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="Communication: Communications Design, Synthesis and Discovery of N,N’�?Carbazoyl�?aryl�?urea Inhibitors of" exact="Zika" post="NS5 Methyltransferase and Virus Replication SpizzichinoSharon12MattediGiulio1LauderKate1ValleCoralie3AouadiWahibaDr.3CanardBrunoDr.3DecrolyEtienneDr.3KapteinSuzanne J. F.Dr.4NeytsJohanProf.4GrahamCarl1SuleZakary1BarlowDavid J.Dr.1SilvestriRomanoProf.2CastagnoloDanieleDr.http://orcid.org/0000-0002-7517-57321daniele.castagnolo@kcl.ac.uk[1],"/>
 <result pre="work is properly cited.file:CMDC-15-385.pdf Abstract Abstract The recent outbreaks of" exact="Zika" post="virus (ZIKV) infection worldwide make the discovery of novel"/>
 <result pre="priority. This work describes the identification of novel inhibitors of" exact="ZIKV" post="through a structure�?based virtual screening approach using the ZIKV"/>
 <result pre="of ZIKV through a structure�?based virtual screening approach using the" exact="ZIKV" post="NS5�?MTase. A novel series of molecules with a carbazoyl�?aryl�?urea"/>
 <result pre="library of analogues has been synthesized. The new compounds inhibit" exact="ZIKV" post="MTase with IC50 between 23–48 μM. In addition, carbazoyl�?aryl�?ureas also"/>
 <result pre="IC50 between 23–48 μM. In addition, carbazoyl�?aryl�?ureas also proved to inhibit" exact="ZIKV" post="replication activity at micromolar concentration. Novel antivirals targeting ZIKA"/>
 <result pre="concentration. Novel antivirals targeting ZIKA virus: The recent outbreaks of" exact="Zika" post="virus (ZIKV) worldwide make the discovery of novel antivirals"/>
 <result pre="series of carbazoyl�?urea derivatives that are able to inhibit the" exact="ZIKV" post="NS5�?MTase as well as ZIKV replication at micromolar concentration."/>
 <result pre="are able to inhibit the ZIKV NS5�?MTase as well as" exact="ZIKV" post="replication at micromolar concentration. Zika flavivirus methyltransferase antiviral agents"/>
 <result pre="ZIKV NS5�?MTase as well as ZIKV replication at micromolar concentration." exact="Zika" post="flavivirus methyltransferase antiviral agents urea Funding European program H2020"/>
 <result pre="D. J. Barlow, R. Silvestri, D. Castagnolo, ChemMedChem2020, 15, 385." exact="Zika" post="virus (ZIKV)1, 2 is a single positive�?strand RNA mosquito�?borne"/>
 <result pre="Flavivirus and it causes mild�?severe diseases in humans and animals." exact="ZIKV" post="is closely related to Dengue virus (DENV), and just"/>
 <result pre="diseases in humans and animals. ZIKV is closely related to" exact="Dengue" post="virus (DENV), and just like DENV, is mainly transmitted"/>
 <result pre="infected Aedes species mosquitoes (Ae. aegypti and Ae. albopictus).3 However," exact="ZIKV" post="can also be transmitted between humans through contact with"/>
 <result pre="by mother�?to�?fetus transmission during the pregnancy.6 While global epidemics of" exact="DENV" post="have spread over the past few decades causing more"/>
 <result pre="past few decades causing more than 20,000 demises per year," exact="ZIKV" post="infections have emerged as a major public health concern"/>
 <result pre="However, following the recent outbreaks in the Americas in 2015," exact="ZIKV" post="was declared by the World Health Organization (WHO) as"/>
 <result pre="of International Concern (PHEIC) and the first case of sexually�?transmitted" exact="ZIKV" post="was reported in USA in 2008. While ZIKV infections"/>
 <result pre="of sexually�?transmitted ZIKV was reported in USA in 2008. While" exact="ZIKV" post="infections generally cause a mild fever, headache, malaise, skin"/>
 <result pre="outbreaks, as well as the increasing number of cases of" exact="ZIKV" post="infections worldwide, have raised the attention of pharmaceutical industries"/>
 <result pre="of efficient treatments against these diseases. Although a vaccine against" exact="DENV" post="has recently been commercialized (DENGVAXIA®),6 there is as yet"/>
 <result pre="been commercialized (DENGVAXIA®),6 there is as yet no vaccine against" exact="ZIKV" post="available. In addition, there are no drugs available to"/>
 <result pre="addition, there are no drugs available to treat or prevent" exact="ZIKV" post="infections, especially in the event of an outbreak. A"/>
 <result pre="number of early�?phase discovery studies have identified few inhibitors of" exact="DENV" post="and ZIKV replication,7, 8, 9, 10, 11, 12, 13,"/>
 <result pre="early�?phase discovery studies have identified few inhibitors of DENV and" exact="ZIKV" post="replication,7, 8, 9, 10, 11, 12, 13, 14, 15"/>
 <result pre="such as 1–5 (Figure 1), have been designed to target the" exact="DENV" post="viral proteins NS3 (protease domain,16 helicase domain,17 and full�?length"/>
 <result pre="RNA�?dependent RNA polymerase (RdRp).20 The NS3 and NS5 proteins of" exact="DENV" post="and ZIKV show a high degree of homology, and"/>
 <result pre="polymerase (RdRp).20 The NS3 and NS5 proteins of DENV and" exact="ZIKV" post="show a high degree of homology, and their crystal"/>
 <result pre="their crystal structures have recently been determined.21, 22, 23 While" exact="DENV" post="NS5�?polymerase has been investigated by a number of research"/>
 <result pre="antivirals, there has been very little work carried out on" exact="DENV" post="and ZIKV NS5�?MTase.18, 23, 24 The NS5�?MTase is responsible"/>
 <result pre="has been very little work carried out on DENV and" exact="ZIKV" post="NS5�?MTase.18, 23, 24 The NS5�?MTase is responsible for maturation"/>
 <result pre="anti�?DENV, antivirals.24 Figure 1 Examples of small molecules active against" exact="DENV" post="and/or ZIKV, and overview of this work. Herein, a"/>
 <result pre="virtual screening on a set of chemical libraries using the" exact="ZIKV" post="NS5�?MTase was performed, with the aim to identify structurally"/>
 <result pre="to identify structurally novel flaviviruses inhibitors. The structure of the" exact="ZIKV" post="NS5 MTase was built by homology modelling using SWISS�?MODEL28,"/>
 <result pre="urea 6 was thus evaluated in enzymatic inhibition assays against" exact="ZIKV" post="NS5�?MTase, showing an IC50 of 35 μM (Table 1). A similar"/>
 <result pre="IC50 of 38 μM was observed when 6 was assayed against" exact="DENV" post="NS5�?MTase. Due to the novelty of the structure when"/>
 <result pre="favorable binding pose of the hit compound 6 in the" exact="ZIKV" post="NS5�?MTase binding pocket. The urea spacer connects the carbazole"/>
 <result pre="with the protein. The high sequence and structural identity between" exact="ZIKV" post="and DENV NS5�?MTases led to the identical binding of"/>
 <result pre="protein. The high sequence and structural identity between ZIKV and" exact="DENV" post="NS5�?MTases led to the identical binding of compound 6"/>
 <result pre="11 and 21 against host and flavivirus MTases. Compd hRNMT" exact="ZIKV" post="NS5�?MTase DENV NS5�?MTase IC50 [μM] 6 13.9±0.7 35±5 38±6.7"/>
 <result pre="21 against host and flavivirus MTases. Compd hRNMT ZIKV NS5�?MTase" exact="DENV" post="NS5�?MTase IC50 [μM] 6 13.9±0.7 35±5 38±6.7 9a ≈122"/>
 <result pre="Verlag GmbH &amp;amp; Co. KGaA, Figure 2 a) SAM bound" exact="ZIKV" post="NS5 MTase in PDB 5M5B.23 b) Docking of compound"/>
 <result pre="MTase in PDB 5M5B.23 b) Docking of compound 6 in" exact="ZIKV" post="NS5 MTase. The carbazole pocket is accommodated in the"/>
 <result pre="of the binding pocket. c) Docking of compound 6 in" exact="DENV" post="NS5�?MTase (PDB 5E9Q).24 Next, a library of analogues of"/>
 <result pre="viral and the human MTases (NS5 and hRNMT). However, both" exact="ZIKV" post="and DENV NS5�?MTase possess a hydrophobic pocket located near"/>
 <result pre="the human MTases (NS5 and hRNMT). However, both ZIKV and" exact="DENV" post="NS5�?MTase possess a hydrophobic pocket located near the exocyclic"/>
 <result pre="of SAM,18 which is absent in the hRNMT. In the" exact="ZIKV" post="MTase, the region is defined by the amino acids"/>
 <result pre="residues F133, I147, G148, E149, R160, and V164 in the" exact="DENV" post="MTase. We anticipated that the absence of this hydrophobic"/>
 <result pre="to hRNTM (PDB 5E8J).30 b) Docking of compound 21 b in" exact="ZIKV" post="NS5 MTase. The ethyl spacer on the carbazole nitrogen"/>
 <result pre="recombinant MTases. All compounds were initially screened at 50 μM against" exact="ZIKV" post="NS5�?MTase and hRNMT as well as against DENV NS5�?MTase"/>
 <result pre="50 μM against ZIKV NS5�?MTase and hRNMT as well as against" exact="DENV" post="NS5�?MTase due to its similarity with ZIKV protein. The"/>
 <result pre="well as against DENV NS5�?MTase due to its similarity with" exact="ZIKV" post="protein. The SAM mimetic sinefungin was included as control."/>
 <result pre="9 a, 9 d, 21 b, 21 c, 21 e and 21 f showed inhibition of" exact="ZIKV" post="NS5�?MTase higher than ∼30 %. The compound 21 e and 21 f"/>
 <result pre="compound 21 e and 21 f showed the more potent reduction of" exact="ZIKV" post="NS5�?MTase activity of ∼70 %. Conversely the compounds 15 and"/>
 <result pre="and those of series 11 and 14 barely inhibited the" exact="ZIKV" post="MTase. Interestingly compound 6 and those of the series"/>
 <result pre="of the series 9 showed a similar inhibition profile on" exact="DENV" post="NS5�?MTase, but the compounds of series 21 barely inhibit"/>
 <result pre="NS5�?MTase, but the compounds of series 21 barely inhibit the" exact="DENV" post="MTase suggesting some specificity of this family. A dose�?response"/>
 <result pre="did not affect the inhibitory activity of the compound against" exact="ZIKV" post="MTase, whilst it proved to be detrimental for inhibiting"/>
 <result pre="MTase, whilst it proved to be detrimental for inhibiting the" exact="DENV" post="MTase. Similarly, the replacement of the electron withdrawing nitro"/>
 <result pre="9 f) negatively affected the compound's inhibitory activity mainly against the" exact="ZIKV" post="MTase. The different activity of compounds 6 and 9"/>
 <result pre="compounds. Derivatives 21 c, 21 e and 21 f showed good activity against" exact="ZIKV" post="MTase at concentrations similar to 6 (IC50=23–48 μM). It is"/>
 <result pre="of all the derivatives synthesized in this work to inhibit" exact="ZIKV" post="replication was assessed. Results of the most active compounds,"/>
 <result pre="activity against ZIKV. Table 2 EC50 and CC50 values against" exact="ZIKV" post="of the most active compounds of the library. Compd"/>
 <result pre="ZIKV of the most active compounds of the library. Compd" exact="ZIKV" post="EC50 [μM] CC50 [μM] 6 &amp;gt;3.99 3.99 9a &amp;gt;50"/>
 <result pre="21b 12.5 20 21d 25 100 21f &amp;gt;20 20 Compd" exact="DENV" post="EC50 [μM] CC50 [μM] 15 9.75 20 (C) Wiley�?VCH"/>
 <result pre="MTase activity. This could explain the very poor inhibition of" exact="ZIKV" post="replication in the cell�?based assay, as the 2′�?O methylation"/>
 <result pre="showed some MTase inhibitory activity, also exhibited antiviral activity against" exact="ZIKV" post="in the cell�?based assay (EC50=4.78 μM). Interestingly, derivative 15,31 which"/>
 <result pre="Interestingly, derivative 15,31 which did not show any activity against" exact="ZIKV" post="NS5�?MTase, was able to inhibit ZIKV replication with an"/>
 <result pre="show any activity against ZIKV NS5�?MTase, was able to inhibit" exact="ZIKV" post="replication with an EC50 of 1.67 μM. It is plausible"/>
 <result pre="an EC50 of 1.67 μM. It is plausible that 15 inhibits" exact="ZIKV" post="replication via a different mode of action than via"/>
 <result pre="treated cells. Interestingly, compound 15 also showed some activity against" exact="DENV" post="(EC50=9.75 μM), even if the antiviral activity is clearly linked"/>
 <result pre="(CC50=20 μM). Finally, compound 21 b which showed no enhanced activity against" exact="ZIKV" post="MTases, proved to inhibit ZIKV replication at good concentration"/>
 <result pre="showed no enhanced activity against ZIKV MTases, proved to inhibit" exact="ZIKV" post="replication at good concentration (EC50=12.5 μM). However, compound 21 b showed"/>
 <result pre="assay as well as 21 f which was found active on" exact="ZIKV" post="MTase instead. This could suggest that these compounds might"/>
 <result pre="virus replication. Interestingly, compound 21 d, which showed poor inhibition of" exact="ZIKV" post="MTase, inhibits ZIKV with good EC50=25 μM and no toxicity"/>
 <result pre="compound 21 d, which showed poor inhibition of ZIKV MTase, inhibits" exact="ZIKV" post="with good EC50=25 μM and no toxicity (CC50=100 μM). In summary,"/>
 <result pre="screening protocol on a set of chemical libraries using the" exact="ZIKV" post="NS5�?MTase was performed leading to the identification of a"/>
 <result pre="Compounds 6 and 21 c, 21 e, 21 f showed inhibitory activity against" exact="ZIKV" post="MTase as well as the related DENV MTase. Conversely,"/>
 <result pre="inhibitory activity against ZIKV MTase as well as the related" exact="DENV" post="MTase. Conversely, the urea derivative 15 showed an antiviral"/>
 <result pre="Conversely, the urea derivative 15 showed an antiviral effect against" exact="ZIKV" post="with EC50 of 1.67 μM, despite its poor inhibitory activity"/>
 <result pre="Med.2016, 374, 1552–1563.27028561 3European Centre for Disease Prevention and Control," exact="Zika" post="Virus disease. https://ecdc.europa.eu/en/zika-virus-disease 4A.Hajra, D.Bandyopadhyay, L. R.Bhadra, S.Ball, S."/>
 <result pre="28When the work was carried out, the 3D structure of" exact="ZIKV" post="NS5-MTase was not elucidated yet. Thus, a homology model"/>
 <result pre="not elucidated yet. Thus, a homology model based on the" exact="DENV" post="NS5 MTase was built. The homology model was then"/>
 <result pre="homology model was then compared to the 3D structure of" exact="ZIKV" post="NS5MTase once it was released, showing full similarity. 29A.Waterhouse,"/>
 <result pre="44, 10423–10436.27422871 31Compound 15 did not show any effect on" exact="DENV" post="MTase and poorly inhibited the ZIKV MTase (25 % of"/>
 <result pre="show any effect on DENV MTase and poorly inhibited the" exact="ZIKV" post="MTase (25 % of inhibition). For this reason, the IC50"/>
 <result pre="of inhibition). For this reason, the IC50 of 15 against" exact="ZIKV" post="MTase was not determined."/>
</results>
